STEVEN C GILMAN
CIK 1379970 · CEO · last filed 2025-06-30
STEVEN C GILMAN is a CEO who has filed 138 SEC Form 4 insider transactions across 9 companies since 2008. The most recent filing, for SCYX, was dated Jun 30, 2025. Across all open-market trades the lifetime net is −$18.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $739.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$739.7K
9
138
-$17.97M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SCYX | Director | 8,750 | $3.63 | $31.8K | $25.0K | 27 | 2025-06-30 |
| AKBA | Director | 152,830 | $1.27 | $194.1K | -$52.1K | 11 | 2025-06-11 |
| VCEL | Director | 11,000 | $46.71 | $513.8K | -$2.23M | 22 | 2024-10-18 |
| CONTRAFECT Corp (CFRX) Delisted | Director | 26 | $0.05 | $1 | $992 | 9 | 2022-05-18 |
| MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Director | 0 | — | — | -$1.10M | 10 | 2020-10-01 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 0 | — | — | -$13.8K | 6 | 2018-12-13 |
| CONTRAFECT Corp (CFRX.W) Delisted | CEO | 20,000 | — | — | $49.6K | 3 | 2016-07-27 |
| CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted | EVP & Chief Scientific Officer | 2,851 | — | — | -$9.24M | 10 | 2015-01-21 |
| CUBIST PHARMACEUTICALS INC (CBST) Delisted | EVP & Chief Scientific Officer | 26,269 | — | — | -$5.41M | 35 | 2013-07-02 |
Recent Filings
138 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-30 | SCYX | Grant (A) | +23,000 | $0 | EDGAR |
| 2025-06-11 | AKBA | Grant (A) | +35,700 | $0 | EDGAR |
| 2025-05-30 | VCEL | Notice (144) | −13,125 | -$551.2K | EDGAR |
| 2024-10-18 | VCEL | Mixed | — | -$165.1K | EDGAR |
| 2024-10-16 | VCEL | Notice (144) | −5,833 | -$241.3K | EDGAR |
| 2024-10-04 | VCEL | Mixed | — | -$159.2K | EDGAR |
| 2024-10-02 | VCEL | Notice (144) | −5,833 | -$235.4K | EDGAR |
| 2024-09-20 | VCEL | Mixed | — | -$189.5K | EDGAR |
| 2024-09-18 | VCEL | Notice (144) | −5,834 | -$265.7K | EDGAR |
| 2024-09-05 | VCEL | Mixed | — | -$224.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.